Skip to main content
Signal8

ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ProMIS Neurosciences, Inc. logo

ProMIS Neurosciences, Inc.

NASDAQ:PMNHealthcare
-6.34%$3.10
Mkt Cap$27.89M
EV-
Float6.67M
O/S9M
VOL94K sh
$ Vol$302K
RVOL0.23×
Inst Own85.2%
SI4.1%
Net Cash/Sh-
Dilution
ProMIS Neurosciences, Inc. logoNASDAQ:PMN$3.10-6.34%
Upcoming Catalysts
  • PMN310READOUT
    Cash runway at this date: 3mo
    First quarter of 2027~19w8-K
Pipeline2 lead-sponsored trials·1 active1 completed

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • Ossianix, Inc.LICENSE IN
    Nov 17, 2026
    TXP1PMN310PMN442PMN267
Clinical Trials
Status
  • Phase 1
    Completed

    A Phase 1a Study of PMN310 In Healthy Volunteers

    PMN310, Placebo

    Healthy Participants

    Enrollment
    40
    Start
    Nov 2023
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT06105528
  • Phase 1
    Active, not recruiting

    PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

    PMN310, Placebo

    Alzheimer Disease, Early Onset

    Enrollment
    144
    Start
    Dec 2024
    Primary Completion
    Dec 2026est.READOUT
    Completion
    Dec 2026est.
    NCT06750432